The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .
Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
Impaired fibrinolytic function , mainly due to increased plasma plasminogen activator inhibitor-1 ( PAI-1 ) activity , is common in patients with manifest coronary artery disease ( CAD ) and a predictor of recurrent cardiovascular events . We investigated the relationships of plasma tissue-type plasminogen activator ( tPA ) and PAI-1 antigen levels , plasma PAI-1 activity and PAI 4/5-guanosine ( 4G/5 G ) genotype to CAD progression in 203 middle-aged men participating in the Lopid Coronary Angiography Trial ( LOCAT ) . A higher tPA antigen concentration , whether baseline or on-trial , was associated with a more severe global angiographic response ( p < 0.05 ) , an association mainly accounted for by progression of diffuse lesions in graft-affected segments ( change in per-patient means of average diameters of segments haemodynamically related to bypass grafts ) . Plasma PAI-1 activity and mass concentration and 4G/5 G PAI-1 genotype were unrelated to angiographic outcome measurements . tPA and PAI-1 antigen increased significantly in the gemfibrozil group ( + 11.3 % and + 16.4 % , respectively , p < 0.001 ) , whereas there was no treatment effect on PAI-1 activity ( median change 0.0 % ) . It is concluded that fibrinolytic function does not substantially influence progression of CAD as assessed by angiography in middle-aged men . Furthermore , pronounced long-term lowering of serum triglycerides by gemfibrozil treatment does not significantly affect the plasma PAI-1 activity level but increases the plasma tPA and PAI-1 antigen concentrations
The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .